Literature DB >> 10759249

Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: human glandular stomach as a site of immune privilege.

S Koyama1.   

Abstract

H. pylori infection almost invariably results in chronic gastritis, but only a proportion of patients develops severe destruction of epithelial glandular structure or peptic ulcer. To confirm the recent data obtained in testis and eye, showing that Fas ligand is involved in the phenomenon of "immune privilege," expression of Fas receptor and its ligand of the stomach was investigated in a panel of gastric biopsies obtained from patients H. pylori-positive (N = 42) and with H. pylori-negative (N = 18) by two-color flow cytometry. The results show that membrane-bound Fas ligand protein is constitutively expressed on freshly isolated human gastric mucosal epithelium coupled with infiltrating lymphocytes. There was significant overexpression of Fas receptor and its ligand, and a higher frequency of apoptotic cell death detected by TUNEL in epithelium and infiltrating lymphocytes in H. pylori-infected patients. These findings suggest that involvement of Fas receptor and its ligand system contributes to some extent to mucosal damage in H. pylori-associated gastritis. However, the more specific findings are apoptotic depletion of invading mucosal lymphocytes associated with Fas ligand expression by gastric epithelium. These provide the first direct quantitative evidence to support Fas receptor counterattack and/or paracrine fratricide as a mechanism of immune privilege in vivo in the H. pylori-infected glandular stomach.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759249     DOI: 10.1023/a:1005408113467

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

Review 1.  The Fas counterattack: cancer as a site of immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Immunol Today       Date:  1999-01

2.  Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis.

Authors:  S Koyama; T Maruyama; S Adachi
Journal:  J Cancer Res Clin Oncol       Date:  1999       Impact factor: 4.553

3.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.

Authors:  B Lowin; M Hahne; C Mattmann; J Tschopp
Journal:  Nature       Date:  1994-08-25       Impact factor: 49.962

4.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

Review 5.  Apoptosis by death factor.

Authors:  S Nagata
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

6.  A role for CD95 ligand in preventing graft rejection.

Authors:  D Bellgrau; D Gold; H Selawry; J Moore; A Franzusoff; R C Duke
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

7.  Regulation of gastric epithelial cell growth by Helicobacter pylori: offdence for a major role of apoptosis.

Authors:  S Wagner; W Beil; J Westermann; R P Logan; C T Bock; C Trautwein; J S Bleck; M P Manns
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

8.  Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma.

Authors:  S Koyama; T Maruyama; S Adachi; M Nozue
Journal:  J Cancer Res Clin Oncol       Date:  1998       Impact factor: 4.553

9.  Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis.

Authors:  J Rudi; D Kuck; S Strand; A von Herbay; S M Mariani; P H Krammer; P R Galle; W Stremmel
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

Review 10.  Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation.

Authors:  M J Blaser
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

View more
  8 in total

1.  Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.

Authors:  Li-Ning Xu; Sheng-Quan Zou; Jian-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

2.  Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma.

Authors:  Shohei Koyama
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

3.  Differential expression of intracellular apoptotic signaling molecules in tumor and tumor-infiltrating lymphocytes during development of invasion and/or metastasis of gastric carcinoma.

Authors:  Shohei Koyama
Journal:  Dig Dis Sci       Date:  2003-12       Impact factor: 3.199

4.  Apoptosis of gastric lymphocytes in Helicobacter pylori-infected rhesus macaques.

Authors:  Satya Dandekar; Elizabeth Reay; Jennifer M Taylor; Jay V Solnick
Journal:  Dig Dis Sci       Date:  2003-06       Impact factor: 3.199

5.  Helicobacter pylori induces apoptosis of T- and B-cell lines and translocates mitochondrial apoptosis-inducing factor to nucleus.

Authors:  Manisha Singh; Kashi N Prasad; Ashish Saxena; Surender K Yachha
Journal:  Curr Microbiol       Date:  2006-03-09       Impact factor: 2.188

6.  Coordinate cell-surface expression of matrix metalloproteinases and their inhibitors on cancer-associated myofibroblasts from malignant ascites in patients with gastric carcinoma.

Authors:  Shohei Koyama
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.322

7.  Helicobacter pylori vacuolating toxin A and apoptosis.

Authors:  Joachim Rassow
Journal:  Cell Commun Signal       Date:  2011-11-01       Impact factor: 5.712

Review 8.  Isolation of lymphocytes from the human gastric mucosa.

Authors:  Masaya Iwamuro; Takahide Takahashi; Natsuki Watanabe; Hiroyuki Okada
Journal:  World J Methodol       Date:  2021-07-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.